|
MICROCEPHALY 12, PRIMARY, AUTOSOMAL RECESSIVE
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
CDK6 associates with the centrosome during mitosis and is mutated in a large Pakistani family with primary microcephaly.
|
23918663 |
2013 |
|
MICROCEPHALY 12, PRIMARY, AUTOSOMAL RECESSIVE
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
CDK6 associates with the centrosome during mitosis and is mutated in a large Pakistani family with primary microcephaly.
|
23918663 |
2013 |
|
MICROCEPHALY 12, PRIMARY, AUTOSOMAL RECESSIVE
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
MICROCEPHALY 12, PRIMARY, AUTOSOMAL RECESSIVE
|
0.700 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Rheumatoid Arthritis
|
0.440 |
GeneticVariation
|
disease |
GWASCAT |
Genetic influences on susceptibility to rheumatoid arthritis in African-Americans.
|
30423114 |
2019 |
|
Rheumatoid Arthritis
|
0.440 |
Biomarker
|
disease |
BEFREE |
Non-HLA genes PTPN22, CDK6 and PADI4 are associated with specific autoantibodies in HLA-defined subgroups of rheumatoid arthritis.
|
25138370 |
2014 |
|
Rheumatoid Arthritis
|
0.440 |
GeneticVariation
|
disease |
GWASDB |
Genetics of rheumatoid arthritis contributes to biology and drug discovery.
|
24390342 |
2014 |
|
Rheumatoid Arthritis
|
0.440 |
GeneticVariation
|
disease |
GWASCAT |
Genetics of rheumatoid arthritis contributes to biology and drug discovery.
|
24390342 |
2014 |
|
Rheumatoid Arthritis
|
0.440 |
Biomarker
|
disease |
BEFREE |
These results obtained through a large cohort of European Caucasian SSc patients do not support the implication of CCL21, CD244 and CDK6 genes in the pathogenesis of SSc although these genes were recently identified as RA susceptibility genes.
|
21586211 |
2011 |
|
Rheumatoid Arthritis
|
0.440 |
GeneticVariation
|
disease |
BEFREE |
However, there was no evidence for association of rs42041 (CDK6) and rs6682654 (CD244) with RA susceptibility in this UK population.
|
19435719 |
2010 |
|
Rheumatoid Arthritis
|
0.440 |
GeneticVariation
|
disease |
BEFREE |
The TT and CC/CG genotypes of 2 single-nucleotide polymorphisms, rs4810485 (CD40) and rs42041 (CDK6), respectively, were associated with a higher rate of joint destruction in ACPA-positive RA patients (P=0.003 and P=0.012, respectively), with rs4810485 being significant after Bonferroni correction for multiple testing.
|
19644859 |
2009 |
|
Rheumatoid Arthritis
|
0.440 |
Biomarker
|
disease |
CTD_human |
Common variants at CD40 and other loci confer risk of rheumatoid arthritis.
|
18794853 |
2008 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
CDK6 overexpression attenuated the effects of NR2F2-AS1 siRNA silencing on cancer cell proliferation.
|
31432342 |
2020 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Cyclin dependent kinase 6 (CDK6) plays a crucial role in malignant tumor whereas less is reported in cervical cancer development.
|
30829464 |
2019 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Combine the results of GO and KEGG enrichment analysis of differences proteins between high and low neuroticism with the PPI network, it could be observed that the Alpha-synuclein (SNCA), ATP7A protein (ATP7A), Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-2 (GNG2), cyclin-dependent kinase 6 (CDK6), myeloperoxidase (MPO), azurocidin (AZU1), Histone H2B type 1-H (HIST1H2BH), Integrin alpha-M (ITGAM) and Matrix metalloproteinase-9 (MMP9) might participate in the intrinsic mechanism of neuroticism by regulating response to catecholamine stimulus, catecholamine metabolic process, limbic system development and transcriptional misregulation in cancer pathway.
|
31719821 |
2019 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Methods that reactivate the RB pathway using inhibitors of cyclin-dependent kinases CDK4 and CDK6 are effective in some cancer types and are currently under evaluation for the treatment of lung adenocarcinoma<sup>7-9</sup>.
|
31043741 |
2019 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
A focused PROTAC library hijacking cancer therapeutic target CDK6 was developed.
|
31330105 |
2019 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
CDK4 and CDK6 are kinases with similar sequences that regulate cell cycle progression and are validated targets in the treatment of cancer.
|
31307887 |
2019 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
MicroRNA‑320 (miR‑320) and CDK6 are both involved in the regulation of cell proliferation in various types of cancer.
|
31059102 |
2019 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
This is of particular relevance as CDK4 and CDK6 inhibitors have shown some promising results in other cancer types and are interesting potential treatments for OSCC.
|
31172620 |
2019 |
|
Atrial Fibrillation
|
0.400 |
Biomarker
|
disease |
CTD_human |
Multi-ethnic genome-wide association study for atrial fibrillation.
|
29892015 |
2018 |
|
Atrial Fibrillation
|
0.400 |
Biomarker
|
disease |
CTD_human |
Biobank-driven genomic discovery yields new insight into atrial fibrillation biology.
|
30061737 |
2018 |
|
Atrial Fibrillation
|
0.400 |
GeneticVariation
|
disease |
GWASCAT |
Biobank-driven genomic discovery yields new insight into atrial fibrillation biology.
|
30061737 |
2018 |
|
Atrial Fibrillation
|
0.400 |
GeneticVariation
|
disease |
GWASCAT |
Multi-ethnic genome-wide association study for atrial fibrillation.
|
29892015 |
2018 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In vitro study confirmed CDK6 as the main target in C-glycosyl flavone-treated cancer cell lines.
|
29806604 |
2018 |